Role of Cyclooxygenase-2 (COX-2) and Its Inhibition in Tumor Biology and Radiotherapy

[1]  J. Masferrer,et al.  COX-2 Inhibitors as Radiosensitizing Agents for Cancer Therapy , 2003, American journal of clinical oncology.

[2]  K. Ang,et al.  In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. , 2002, International journal of radiation oncology, biology, physics.

[3]  N. Hayashi,et al.  Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. , 2002, Cancer research.

[4]  Miyuki Saito,et al.  Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. , 2002, The American journal of pathology.

[5]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[6]  M. Zemel,et al.  Prostaglandin E2 Protects Intestinal Tumors from Nonsteroidal Anti-inflammatory Drug-induced Regression in ApcMin/+ Mice , 2002 .

[7]  Y. Bakhle.  COX‐2 and cancer: a new approach to an old problem , 2001, British journal of pharmacology.

[8]  H. Choy,et al.  A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  L. Milas,et al.  Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. , 2001, Seminars in radiation oncology.

[10]  P. Harari,et al.  Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. , 2001, Seminars in radiation oncology.

[11]  A. Dicker,et al.  Targeting Angiogenic Processes by Combination Rofecoxib and Ionizing Radiation , 2001, American journal of clinical oncology.

[12]  Ming Li,et al.  Induction of apoptosis by cyclo‐oxygenase‐2 inhibitor NS398 through a cytochrome C‐dependent pathway in esophageal cancer cells , 2001, International journal of cancer.

[13]  H. Osada,et al.  Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis , 2001, Oncogene.

[14]  A. Grothey,et al.  Cyclooxygenase-2: a novel target for cancer chemotherapy? , 2001, Journal of Cancer Research and Clinical Oncology.

[15]  Li Zhu,et al.  Non-small Cell Lung Cancer Cyclooxygenase-2-dependent Invasion Is Mediated by CD44* , 2001, The Journal of Biological Chemistry.

[16]  S. Lippman,et al.  Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  J. Holden,et al.  Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[18]  W. Kiefer,et al.  Cyclooxygenase inhibitors--current status and future prospects. , 2001, European journal of medicinal chemistry.

[19]  C. Houchen,et al.  Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[20]  K. Seibert,et al.  The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. , 2000, Cancer research.

[21]  Y. Kawahito,et al.  Meloxicam inhibits the growth of non-small cell lung cancer. , 2000, Anticancer research.

[22]  I. Gibbs,et al.  Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. , 2000, International journal of radiation oncology, biology, physics.

[23]  Bert Vogelstein,et al.  Combinatorial chemoprevention of intestinal neoplasia , 2000, Nature Medicine.

[24]  P. Jänne,et al.  Chemoprevention of colorectal cancer. , 2000, The New England journal of medicine.

[25]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[26]  S. Dey,et al.  Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.

[27]  F. Lang,et al.  Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  S. Cohn,et al.  Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. , 2000, Gastroenterology.

[29]  S. Yamashina,et al.  Cyclo‐oxygenase‐2 enhances basic fibroblast growth factor‐induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants , 2000, British journal of pharmacology.

[30]  R. DuBois,et al.  Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. , 2000, Gastroenterology.

[31]  M. Hull,et al.  The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. , 2000, European journal of cancer.

[32]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[33]  P. Tofilon,et al.  Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. , 2000, Cancer research.

[34]  K. Ang,et al.  In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  L. Howells,et al.  Modulation of signal-transduction pathways by chemopreventive agents. , 2000, Biochemical Society transactions.

[36]  Li Zhu,et al.  Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis1 , 2000, The Journal of Immunology.

[37]  E. Fosslien.  Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia , 2000, Critical reviews in clinical laboratory sciences.

[38]  K. Sheahan,et al.  The relationship between cyclooxygenase-2 expression and colorectal cancer. , 1999, JAMA.

[39]  J. Masferrer,et al.  Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. , 1999, Expert opinion on investigational drugs.

[40]  K. Sankaranarayanan,et al.  In vivo and in vitro radioprotective effects of the prostaglandin E1 analogue misoprostol in DNA repair-proficient and -deficient rodent cell systems. , 1999, Radiation research.

[41]  R. Gaynor,et al.  Sulindac Inhibits Activation of the NF-κB Pathway* , 1999, The Journal of Biological Chemistry.

[42]  P. Tofilon,et al.  Enhancement of Tumor Response to γ-Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme , 1999 .

[43]  R. Weichselbaum,et al.  Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .

[44]  J. Morrow,et al.  Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. , 1999, Genes & development.

[45]  Y. Yatabe,et al.  Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  T. Fahey,et al.  Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. , 1999, Cancer research.

[47]  J. Shah,et al.  Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. , 1999, Cancer research.

[48]  H. Shiozaki,et al.  Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma , 1999, American Journal of Gastroenterology.

[49]  C. Hawkey,et al.  COX-2 inhibitors , 1999, The Lancet.

[50]  R. Weichselbaum,et al.  Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. , 1998, Cancer research.

[51]  A. Ristimäki,et al.  Expression of cyclooxygenase-2 in human lung carcinoma. , 1998, Cancer research.

[52]  M. Taketo.  Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). , 1998, Journal of the National Cancer Institute.

[53]  A. Rojiani,et al.  Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. , 1998, International journal of radiation oncology, biology, physics.

[54]  Y. Yatabe,et al.  Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. , 1998, Cancer research.

[55]  S. Meltzer,et al.  Advances in Brief Increased Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Barrett ' s Esophagus and Associated Adenocarcinomas 1 , 2006 .

[56]  A. Watson,et al.  Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. , 1998, Histology and histopathology.

[57]  Li Zhu,et al.  Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. , 1998, Cancer research.

[58]  K. Seibert,et al.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. , 1998, Cancer research.

[59]  K. Kinzler,et al.  Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[61]  R. Kerbel,et al.  Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. , 1996, European journal of cancer.

[62]  Raymond L. White,et al.  Self-Promotion? Intimate Connections Between APC and Prostaglandin H Synthase-2 , 1996, Cell.

[63]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[64]  R. Garavito.  The cyclooxygenase-2 stucture: new drugs for an old target? , 1996, Nature Structural Biology.

[65]  R. DuBois,et al.  Prostaglandin endoperoxide synthase: why two isoforms? , 1996, The American journal of physiology.

[66]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[67]  R. DuBois,et al.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.

[68]  L. Milas,et al.  Eicosanoids and radiation. , 1995, European journal of cancer.

[69]  M. Kondo,et al.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.

[70]  L. Peters,et al.  Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. , 1995, Cancer research.

[71]  S Jothy,et al.  Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. , 1995, Cancer research.

[72]  G. Strassmann,et al.  Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. , 1995, Journal of immunology.

[73]  L. Marnett.  Generation of mutagens during arachidonic acid metabolism , 1994, Cancer Metastasis Review.

[74]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[75]  K. Umesono,et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[76]  D. Braun,et al.  Prostaglandin Inhibitors in Tumor Immunology and Immunotherapy , 1994 .

[77]  B. Rigas,et al.  Altered eicosanoid levels in human colon cancer. , 1993, The Journal of laboratory and clinical medicine.

[78]  N. Zaffaroni,et al.  Differential effect of 9 beta-chloro-16, 16-dimethyl prostaglandin E2 (nocloprost) on the radiation response of human normal fibroblasts and colon adenocarcinoma cells. , 1993, Radiation research.

[79]  F. Malkinson,et al.  Topical or systemic 16, 16 dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation. , 1992, International journal of radiation biology.

[80]  B. Varnum,et al.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.

[81]  A. Haimovitz-Friedman,et al.  Radiation Damage in Endothelial Cells Autocrine Effects of Fibroblast Growth Factor in Repair of Updated , 2006 .

[82]  R. Erikson,et al.  Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[83]  K. Seibert,et al.  The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. , 1990, The Journal of biological chemistry.

[84]  L. Milas,et al.  Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. , 1990, Cancer research.

[85]  L. Milas,et al.  Radioprotection of hematopoietic tissues in mice by indomethacin. , 1990, Radiation research.

[86]  W. Smith,et al.  The eicosanoids and their biochemical mechanisms of action. , 1989, The Biochemical journal.

[87]  L. Milas,et al.  Increase in radioresponse of murine tumors by treatment with indomethacin. , 1988, Cancer research.

[88]  L. Milas,et al.  Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. , 1988, Cancer research.

[89]  A. Fulton.  Interactions of natural effector cells and prostaglandins in the control of metastasis. , 1987, Journal of the National Cancer Institute.

[90]  E. J. Ainsworth,et al.  16,16-Dimethyl prostaglandin E2 induces radioprotection in murine intestinal and hematopoietic stem cells. , 1985, Radiation research.

[91]  W. Hanson,et al.  16, 16-dimethyl prostaglandin E2 increases survival of murine intestinal stem cells when given before photon radiation. , 1983, Radiation research.

[92]  R. Auerbach,et al.  PGE2 and Angiogenesis 1 , 1983, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[93]  P. Gullino,et al.  Role of prostaglandin E1 and copper in angiogenesis. , 1982, Journal of the National Cancer Institute.

[94]  E. Mihich,et al.  Prostaglandin modulation of development of cell-mediated immunity in culture , 1980, Nature.

[95]  R. Herberman,et al.  Inhibition of murine natural killer cell activity by prostaglandins. , 1980, Journal of immunology.

[96]  J. Levy,et al.  The possible role of prostaglandins in mediating immune suppression by nonspecific T suppressor cells. , 1980, Cellular immunology.

[97]  A. Bennett,et al.  Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers [proceedings]. , 1979, British journal of pharmacology.

[98]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[99]  Y. Kakeji,et al.  Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma , 2004, Breast Cancer Research and Treatment.

[100]  S. Gately.  The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis , 2004, Cancer and Metastasis Reviews.

[101]  L. Marnett,et al.  COX-2: a target for colon cancer prevention. , 2002, Annual review of pharmacology and toxicology.

[102]  P. Thompson,et al.  Carcinogen substrate specificity of human COX-1 and COX-2. , 2001, Carcinogenesis.

[103]  K. Ang,et al.  Maximizing therapeutic gain with gemcitabine and fractionated radiation. , 1999, International journal of radiation oncology, biology, physics.

[104]  O'Banion Mk.  Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. , 1999 .

[105]  K. Schrör,et al.  Cyclooxygenase-2 expression in human esophageal carcinoma. , 1999, Cancer research.

[106]  K. Sankaranarayanan,et al.  Differential radioprotective effects of misoprostol in DNA repair-proficient and -deficient or radiosensitive cell systems. , 1997, International journal of radiation biology.

[107]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.

[108]  C. Coleman,et al.  Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts , 1996 .

[109]  L. Milas,et al.  Radiation protection against early and late effects of ionizing irradiation by the prostaglandin inhibitor indomethacin. , 1992, Advances in space research : the official journal of the Committee on Space Research.

[110]  T. Eling,et al.  Xenobiotic metabolism by prostaglandin H synthase. , 1992, Pharmacology & therapeutics.

[111]  A. Gilman,et al.  G proteins: transducers of receptor-generated signals. , 1987, Annual review of biochemistry.